Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and announces Price Target of $18.
Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and announces Price Target of $18.